The Managed Care Review Board™ — An Analysis of Treatment Options, Comparative Effectiveness Research, and Benefit Designs for Rheumatoid Arthritis Web Activity

• Release date: March 23, 2016
• Expiration date: September 30, 2017
• Estimated Time to Complete Activity: 1.5 hours
• Compatible with all modern browsers and mobile devices

Distinguished Faculty

Jeffrey D. Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx Pharmacy Services, LLC Click here for biography Brian Kaye, MD, FACP Rheumatologist Sutter East Bay Medical Foundation Clinical Professor of Medicine University of California at San Francisco Adjunct Professor College of Education and Health Sciences Touro University Click here for biography Neil Minkoff, MD Principal, FountainHead HealthCare Chief Medical Officer EmpiraMed, Inc. Click here for biography Fadia T. Shaya, PhD, MPH Professor and Vice-Chair for Academic Affairs University of Maryland School of Pharmacy Click here for biography

Target Audience

• Medical directors and pharmacy directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with rheumatoid arthritis including: physicians, pharmacists, registered nurses, and case managers

Statement of Need/Program Overview 
Rheumatoid arthritis (RA) is an autoimmune disease affecting nearly 1.5 million adult Americans. There is no cure for RA, but new effective drugs are increasingly available to treat the disease and prevent deformed joints. Currently, the RA therapeutic pipeline is robust and includes agents that utilize novel mechanisms of action (MOAs) and various administration strategies (eg, oral, subcutaneous injection).The Managed Care Review Board™ format features a review of important, relevant therapeutic category information and features peer-to-peer exchange between a diverse group of managed care and clinical specialist faculty contributors.
This interactive program is designed to engage the faculty and audience to develop solutions for managed care professionals to implement within their own setting to improve outcomes for patients with RA. This approach supports managed care pharmacists by enhancing the results of their own health care organization’s systematic literature reviews and analyses.

Educational Objectives
After completing this activity, the participant should be better able to:

• Discuss the current clinical practice guidelines to improve outcomes for patients with RA
• Explain the unique role and utility of CER to improve outcomes for the treatment of RA within a managed care setting
• Cite currently available RA data and interpret the results for enhanced managed care decision-making for the treatment of RA
• Apply the use of CER for the treatment of RA within a managed care setting
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number –0809-9999-16-223-H01-P

Type of Activity
Application

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education

Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Nursing Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period March 23, 2016 through September 30, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.